April 13, 2023
(press release)
–
Unicharm Corporation (CEO & President, Mr. Takahisa Takahara) announced that it has been selected as “All-Star” status for two consecutive years by the leading U.S. financial magazine, Institutional Investor. Unicharm received the first place in all six categories in Best CEO, Best CFO, Best IR Professional, Best IR Program, Best ESG, and Best Company Board, surveyed by 2023 Japan Executive Team Rankings. Institutional Investor is a world-known major U.S. financial magazine. The All-Japan Executive Team survey has been conducted since 2013, and this is the eleventh year. Global institutional investors and analysts participate in the survey, which evaluates financial disclosure, service and communication, ESG, and other factors, and selects Japanese listed companies with outstanding IR activities. The survey results are published in 26 categories for each industry (sector). The 2023 Japan Executive Team Rankings survey result reflects the opinions from 424 investors, portfolio managers and analysts from 172 firms, nominating a total of 505 companies. Unicharm has been commended for obtaining the first place position within the Cosmetics & Personal Care sector in all six categories, i.e., Best CEO, Best CFO, Best IR Professional, Best IR Program, Best ESG, and Best Company Board, which led to being selected as “All-Star” for two consecutive years since 2022. We will continue to pursue further enhancement of our high-quality IR activities and strive for more timely and accurate disclosure so that more shareholders and investors can deepen their understanding of our company. <Related Information> Institutional Investor Unicharm Investor Relations <<For inquiries>> Unicharm Corporation, ESG Division, Public Relations Office Email: brand-pr@unicharm.com
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
